Who Paid My Doc
Robert Drvol
Adolescent Medicine Omaha, NE Medical Doctor
NPI 1508916594 CMS profile 204192
6829 N 72Nd St Ste 3100, Omaha, NE 68122
General payments
$227
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Robert Drvol of Omaha, NE is reported in the CMS Open Payments database as having received $227 across 12 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 39th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $77 | 3 | |
| 2023 | General | $45 | 2 | |
| 2022 | General | $35 | 2 | |
| 2021 | General | $20 | 1 | |
| 2019 | General | $51 | 4 |
Beside peers
- Robert Drvol
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Robert Drvol were reported at $77. Among 113 Adolescent Medicine profiles paid that year, the median was $165 and the middle half received between $61 and $402.
Show as a table
| Year | Robert Drvol | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $51 | $151 | $36–$708 | $163 |
| 2020 | $0 | $123 | $24–$337 | $114 |
| 2021 | $20 | $155 | $54–$620 | $132 |
| 2022 | $35 | $158 | $50–$556 | $149 |
| 2023 | $45 | $170 | $52–$612 | $160 |
| 2024 | $0 | $182 | $65–$431 | $164 |
| 2025 | $77 | $165 | $61–$402 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 170 drugsPart D claims
11,582
Drug cost
$867,655
Branded share of claims
19.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | Brand | 140 | $161,112 | |
| Eliquis Apixaban | Brand | 196 | $142,710 | |
| Ozempic Semaglutide | Brand | 92 | $91,614 | |
| Januvia Sitagliptin Phosphate | Brand | 42 | $52,775 | |
| Jardiance Empagliflozin | Brand | 55 | $48,646 | |
| Trulicity Dulaglutide | Brand | 42 | $41,987 | |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 19 | $30,647 | |
| Xarelto Rivaroxaban | Brand | 27 | $25,370 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 28 | $23,493 | |
| Farxiga Dapagliflozin Propanediol | Brand | 14 | $16,761 |
The 10 drugs with the highest cost, of 170 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 59 billing codesPaid by Medicare
$118,960
Medicare patients
435
Services billed
4,065
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Arthritis | 59% | |
| Diabetes | 28% | |
| Depression | 25% | |
| Ischemic heart disease | 22% | |
| Chronic kidney disease | 20% | |
| Atrial fibrillation | 18% | |
| Cancer | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Pcv20 vaccine im 90677 | Office | 13 | 13 | $3,769 |
| Vaccine for influenza for injection into muscle 90653 | Office | 33 | 33 | $2,700 |
| Sarscv2 vac 30mcg trs-suc im 91320 | Office | 13 | 15 | $2,146 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 11 | 960 | $99 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 14 | 60 | $5 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adolescent Medicine in Nebraska
Related records
Adolescent Medicine in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.